Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with exploratory analysis to predict treatment efficacy and prognosis
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620655
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: FOLFIRI+panitumumab
FOLFIRI+bevacizumab
Primary outcome(s): Overall survival
Study Design: Parallel Randomized
创建时间：
2011-04-15
